Decrease of rapid-eye-movement sleep in the light by intraventricular application of a VIP-antagonist in the rat

Brain Res. 1988 Aug 16;458(1):192-4. doi: 10.1016/0006-8993(88)90516-1.

Abstract

Vasoactive intestinal polypeptide (VIP) has been shown to increase the amount of time spent in rapid-eye-movement (REM) sleep both in cats and in rats. In the present study we examined the effect of a newly available competitive VIP-antagonist ([4Cl-D-Phe6-Leu17]-VIP) on sleep-wake patterns in male rats during both the light and the dark phase of 24 h. Continuous intracerebroventricular application of this VIP-antagonist reduced by 44% the amount of time spent in REM sleep during the light period. It is concluded that VIP may play a role in the generation and maintenance of REM sleep.

MeSH terms

  • Animals
  • Cerebral Ventricles / drug effects
  • Cerebral Ventricles / physiology*
  • Injections, Intraventricular
  • Rats
  • Rats, Inbred Strains
  • Reference Values
  • Sleep, REM / drug effects*
  • Vasoactive Intestinal Peptide / analogs & derivatives*
  • Vasoactive Intestinal Peptide / antagonists & inhibitors*
  • Vasoactive Intestinal Peptide / pharmacology

Substances

  • vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-
  • Vasoactive Intestinal Peptide